Denali Therapeutics Inc (NASDAQ:DNLI) has received a consensus broker rating score of 1.83 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company.
Brokers have set a 12 month consensus target price of $24.67 for the company and are expecting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given Denali Therapeutics an industry rank of 187 out of 265 based on the ratings given to its competitors.
Several equities research analysts have recently weighed in on DNLI shares. Morgan Stanley began coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 price target on the stock. Evercore ISI began coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 price objective for the company. Goldman Sachs Group began coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued a “neutral” rating for the company. Finally, JPMorgan Chase & Co. began coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 price objective for the company.
Institutional investors have recently modified their holdings of the company. Landscape Capital Management L.L.C. acquired a new position in Denali Therapeutics in the fourth quarter valued at approximately $166,000. MYDA Advisors LLC acquired a new position in Denali Therapeutics during the fourth quarter worth $188,000. Gilder Gagnon Howe & Co. LLC acquired a new position in Denali Therapeutics during the fourth quarter worth $237,000. Wolverine Asset Management LLC acquired a new position in Denali Therapeutics during the fourth quarter worth $249,000. Finally, Wells Fargo & Company MN acquired a new position in Denali Therapeutics during the fourth quarter worth $621,000. Institutional investors and hedge funds own 65.45% of the company’s stock.
Denali Therapeutics (NASDAQ:DNLI) traded up $1.77 during trading on Wednesday, reaching $21.89. The company had a trading volume of 377,960 shares, compared to its average volume of 234,868. Denali Therapeutics has a 12 month low of $14.72 and a 12 month high of $25.79. The stock has a market capitalization of $1,930.00 and a PE ratio of -21.25.
WARNING: “Denali Therapeutics Inc (DNLI) Receives Average Rating of “Buy” from Analysts” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/14/denali-therapeutics-inc-dnli-receives-average-rating-of-buy-from-analysts.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.